Open AccessOridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway
Author(s) -
Xuguang Li,
Weirun Chen,
Kaihang Liu,
Sheng Zhang,
Ru Yang,
Kairui Liu,
Dateng Li,
Youxing Huang
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s257482
Subject(s) - sorafenib , protein kinase b , hepatocellular carcinoma , cancer research , mapk/erk pathway , apoptosis , in vivo , chemistry , pharmacology , pi3k/akt/mtor pathway , cell growth , epithelial–mesenchymal transition , flow cytometry , mtt assay , signal transduction , medicine , biology , metastasis , immunology , cancer , biochemistry , microbiology and biotechnology
Oridonin is the core bioactive component of Rabdosia rubescens , a traditional Chinese herbal medicine used in the treatment of hepatoma. Sorafenib, a targeted therapeutic agent for advanced hepatocellular carcinoma (HCC), has recently been shown to exert limited clinical effects. However, few studies have focused on the synergistic effect of these two drugs on hepatocellular carcinoma.